Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142714 | 0.93 | MEN1 (0.44) | CYP3A4CHRNA7CYP2C9RBP4MEN1 | |
| SCHEMBL2133613 | 0.93 | MEN1 (0.44) | CYP3A4CHRNA7CYP2C9RBP4MEN1 | |
| SCHEMBL2135364 | 0.87 | RBP4 (0.45) | CYP3A4CHRNA7CYP2C9RBP4MGLL | |
| SCHEMBL2129853 | 0.84 | RBP4 (0.43) | CYP3A4CHRNA7CYP2C9RBP4MGLL | |
| SCHEMBL2132028 | 0.82 | EPHX1 (0.42) | CHRNA7MEN1RAB9AKMT2AHRH4 | |
| SCHEMBL2732825 | 0.82 | CCR2 (0.43) | CYP3A4CHRNA7CYP2C9RBP4MGLL | |
| SCHEMBL2129688 | 0.82 | CCR2 (0.43) | CYP3A4CHRNA7CYP2C9RBP4MGLL | |
| SCHEMBL2132384 | 0.82 | CHRNA7 (0.39) | CHRNA7MEN1RAB9AKMT2AMGLL | |
| SCHEMBL2131995 | 0.82 | ALDH1A1 (0.40) | CYP3A4CYP2C9RBP4MEN1RAB9A | |
| SCHEMBL2130576 | 0.82 | CYP3A4 (0.52) | CYP3A4CYP2C9RBP4MGLLKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | claimed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | claimed |
| EP-2630139-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-28 | — | — | EP | claimed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | claimed |
| WO-2012054721-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICAL NV (BE) | 2012-04-26 | — | — | WO | claimed |
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | disclosed |
| EP-2630139-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-08-28 | — | — | EP | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054721-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICAL NV (BE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | CYP3A4 2393/4885CHRNA7 3677/4885CYP2C9 592/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | CYP3A4 2393/4885CHRNA7 3677/4885CYP2C9 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.